<DOC>
	<DOCNO>NCT00246324</DOCNO>
	<brief_summary>To evaluate efficacy , safety , tolerability combination therapy intramuscular interferon beta-1a oral doxycycline , potent inhibitor matrix metalloproteinases , patient relapse remit multiple sclerosis ( RRMS ) breakthrough disease activity .</brief_summary>
	<brief_title>Safety Efficacy Study Doxycycline Combination With Interferon-B-1a Treat Multiple Sclerosis</brief_title>
	<detailed_description>Eligible individual evaluate monthly 3 month take intramuscular interferon beta-1a , 30 microgram weekly , monthly 4 month receive intramuscular interferon beta-1a , 30 microgram oral doxycycline , 100 mg daily .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>age 1855 RelapsingRemitting Multiple Sclerosis ( RRMS ) Avonex therapy 6 month prior continuous annualized relapse rate &gt; 2 Avonex therapy recent relapse within 60 day baseline entry Expanded Disability Status Scale ( EDSS ) 1.54.5 one gadolinium ( Gd+ ) MRI lesion baseline MRI history immune modulator immunosuppressant therapy use combination Avonex ( GSC administer clinical relapse ) participate study m therapeutic Serum neutralize antibody ( NABs ) titer Avonex &lt; 20 Medical Psychiatric condition affect patient ability provide inform consent inability undergo MRI clinically serious medical condition significantly abnormal lab use medication procedure within six month prior study : *monoclonal antibody , total lymphoid radiation , systemic steroid , cytotoxic immunosuppressive medication mitoxantrone cyclophosphamide investigational drug Interferon neutralize antibody titer &gt; 20 breast feeding pregnant patient systemic illness , psychiatric condition disorder would concern safety patient complete procedure protocol abnormal blood test clinically significant abnormality chest xray ( CXR )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>